Metabolic Effects of Angiotensin-(1-7)
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-60
SponsorVanderbilt University
About this trial
The overall purpose of this study is to learn more about the metabolic effects of angiotensin-(1-7) in the insulin resistant state associated with obesity. Pharmacologic approaches to increase angiotensin-(1-7) levels or its actions are currently in development for treatment of metabolic-related diseases such as obesity and type II diabetes, based on findings from animal studies. It is unclear if this peptide contributes to the regulation of metabolism in humans. The investigators will test if angiotensin-(1-7) infusion can improve insulin sensitivity measured by hyperinsulinemic-euglycemic clamp methods in individuals with obesity and insulin resistance. The investigators will also examine for changes in blood pressure and related hemodynamic and hormonal changes following angiotensin-(1-7) infusion.
Eligibility criteria
Qualifiers
Males and females of all races between 18 and 60 years of age
Obesity defined as body mass index between 30-40 kg/m2
Insulin resistance defined as homeostasis model assessment 2 insulin resistance (HOMA2-IR) score >2.2
Hypertension defined by two or more properly measured seated blood pressure readings >130/85 mmHg, or by use of anti-hypertensive medications. This blood pressure cutoff will allow us to include subjects with pre-hypertension.
Disqualifiers
Pregnancy or breast-feeding
Current smokers or history of heavy smoking (>2 packs/day)
History of alcohol or drug abuse
Morbid obesity (BMI > 40 kg/m2)
Trial design
Treatments tested in this trial
- Angiotensin-(1-7)
- Saline
Treatment groups
26 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov